INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Stuttgart
15.05.26 | 21:56
1,680 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,680 | 1,760 | 13:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:46 | Innate Pharma übertrifft Erwartungen - Aktie steigt vorbörslich um fast 60 % | 2 | Investing.com Deutsch | ||
| Mi | Innate Pharma SA - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| Mi | Innate Pharma reports Q1 results | 8 | Seeking Alpha | ||
| Mi | Innate Pharma SA: Innate Pharma Reports First Quarter 2026 Business Update and Financial Results | 384 | Business Wire | Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation... ► Artikel lesen | |
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| Di | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026 | 247 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 06.05. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.05. | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update | 310 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Wednesday, May 13, 2026 at 1:30... ► Artikel lesen | |
| 23.04. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.04. | Innate Pharma SA: Innate Pharma to Participate in the D. Boral Capital Global Conference | 291 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 17.04. | Innate Pharma legt Zwischenergebnisse zu Lungenkrebsstudie vor | 1 | Investing.com Deutsch | ||
| 17.04. | Innate Pharma reports interim lung cancer trial results | 1 | Investing.com | ||
| 17.04. | Innate Pharma SA: Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 | 487 | Business Wire | Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and... ► Artikel lesen | |
| 13.04. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.04. | Innate Pharma SA: Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026 | 333 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") will hold its Annual General Meeting of shareholders ("AGM") at 10:30 a.m. CEST on May 21, 2026... ► Artikel lesen | |
| 13.04. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 | 337 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 08.04. | Innate Pharma SA: Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event | 357 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), announced today that Yannis Morel, Chief Operating Officer, will present at the AACR Oncology... ► Artikel lesen | |
| 03.04. | Innate Pharma SA: Innate Pharma to Participate in the Kempen Life Sciences Conference | 558 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 02.04. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 02.04. | Innate Pharma SA: Innate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual Report | 358 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the filing of its 2025 Universal Registration Document (Document d'enregistrement... ► Artikel lesen | |
| 01.04. | Innate Pharma SA - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,540 | +0,95 % | Valneva senkt Prognose und baut Stellen ab | Beim Impfstoffspezialisten Valneva SE häufen sich im ersten Quartal 2026 die Belastungen: Der Nettoverlust weitete sich auf 32,1 Millionen Euro nach 9,2 Millionen Euro im Vorjahr aus, das bereinigte... ► Artikel lesen | |
| NOVAVAX | 7,800 | 0,00 % | Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes | ||
| OCUGEN | 1,182 | -1,66 % | Ocugen schließt Platzierung von Wandelanleihen über 130 Millionen US-Dollar ab | ||
| INFLARX | 1,950 | -8,45 % | InflaRx schließt Kapitalerhöhung über 150 Millionen Dollar ab | Wie angekündigt hat InflaRx die Platzierung von 75 Millionen Stammaktien zu je 2,00 US-Dollar abgeschlossen. Der Bruttoerlös beläuft sich nach Angaben des Jenaer Biotechnologie-Unternehmens auf 150... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,580 | -1,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE... ► Artikel lesen | |
| EDITAS MEDICINE | 2,250 | -0,44 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,245 | -0,80 % | Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,912 | +1,88 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,240 | +0,93 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 0,985 | +1,69 % | PacBio: HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss | ||
| CARDIOL THERAPEUTICS | 1,152 | +1,05 % | Stocks in Play: Cardiol Therapeutics Inc. | ||
| GERON | 1,155 | +3,63 % | Geron Corporation: First Real-World Evidence Study of RYTELO (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 | ||
| ARBUTUS BIOPHARMA | 3,610 | -1,10 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| IMMUNITYBIO | 6,810 | -0,87 % | ImmunityBio-Aktie -21%: Buy the dip? | Es ist eine nervenaufreibende Woche für ImmunityBio-Aktionäre. Nachdem der Kurs des Biotech-Unternehmens am Montag +10% in die Höhe schoss, ging es am gestrigen Dienstag um atemberaubende -21% nach... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,625 | +1,56 % | Microbot Medical plunges amid results, short report from White Diamond Research |
INNATE PHARMA SA ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,680 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.